Matching trials
2,411 results
- QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma: Complete Statistical AnalysisIndependent statistical analysis of QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02383498).
- QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer: Complete Statistical AnalysisIndependent statistical analysis of QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- QUORUMIndependent statistical analysis of Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- R-CHOPIndependent statistical analysis of Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas: Complete Statistical AnalysisIndependent statistical analysis of R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RA-MOBILITYComplete statistical analysis of RA-MOBILITY, evaluating sarilumab on top of methotrexate in rheumatoid arthritis, including ACR20 response, HAQ-DI, structural damage, multiplicity, and registry-reported statistical results.
- RAD 2003Independent statistical analysis of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04743934).
- RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment: Complete Statistical AnalysisIndependent statistical analysis of RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RAD001 Plus Bevacizumab in Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of RAD001 Plus Bevacizumab in Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00591734).
- Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Radiation Therapy to Treat Musculoskeletal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy to Treat Musculoskeletal Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00186992).
- Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Radiosurgery for Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Radiosurgery for Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00456612).
- Radiotherapy for Solid Tumor Spine Metastases: Complete Statistical AnalysisIndependent statistical analysis of Radiotherapy for Solid Tumor Spine Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01752036).
- RAINBOIndependent statistical analysis of the RAINBO phase 2/3 trial of molecularly guided adjuvant treatment strategies in endometrial cancer, including trial design, recurrence-free survival endpoints, planned statistical analysis, and interpretation.
- RAMENIndependent statistical analysis of A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration: primary endpoint results, effect…
- Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.: Complete Statistical AnalysisIndependent statistical analysis of Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.: primary endpoint results,…
- Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC): Complete Statistical AnalysisIndependent statistical analysis of Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…
- Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy: Complete Statistical AnalysisIndependent statistical analysis of Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02203695).
- Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs: Complete Statistical AnalysisIndependent statistical analysis of Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs: primary endpoint results, effect estimate…
- Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD: Complete Statistical AnalysisIndependent statistical analysis of Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RANIAIndependent statistical analysis of Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants…
- RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS: Complete Statistical AnalysisIndependent statistical analysis of RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00126672).
- Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence: Complete Statistical AnalysisIndependent statistical analysis of Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP: Complete Statistical AnalysisIndependent statistical analysis of Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RAPID KORIndependent statistical analysis of Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RasbAKIIndependent statistical analysis of Lowering Serum Uric Acid to Prevent Acute Kidney Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756964).
- Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2: Complete Statistical AnalysisIndependent statistical analysis of Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rasburicase in Patients at Risk for Tumor Lysis Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Rasburicase in Patients at Risk for Tumor Lysis Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00628628).
- RDVCGHIndependent statistical analysis of Racial Differences in Vagal Control of Glucose Homeostasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02365285).
- RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome: Complete Statistical AnalysisIndependent statistical analysis of RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Re-expression of ER in Triple Negative Breast Cancers: Complete Statistical AnalysisIndependent statistical analysis of Re-expression of ER in Triple Negative Breast Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01194908).
- Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size…
- REACH 5Independent statistical analysis of Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant: primary endpoint results, effect estimate with confidence…
- RECAD-AFIndependent statistical analysis of Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ReCLAIM-2Independent statistical analysis of ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928030).
- RECORD-4Independent statistical analysis of Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01491672).
- REDIRECTIndependent statistical analysis of Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence…
- Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease: Complete Statistical AnalysisIndependent statistical analysis of Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease: primary endpoint results, effect…
- Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers: Complete Statistical AnalysisIndependent statistical analysis of Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Reducing Preterm Births in Underserved Pregnant Women: Complete Statistical AnalysisIndependent statistical analysis of Reducing Preterm Births in Underserved Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01344616).